Cargando…
Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome
Performance of the QuantiFERON-TB Gold Plus (QFT-Plus) assay could be affected by conditions of immune dysregulation. Little is known about the reliability of QTF-Plus in COVID-19 patients. Our aim was to determine the prevalence and the factors related to an indeterminate QFT-Plus test in COVID-19...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956705/ https://www.ncbi.nlm.nih.gov/pubmed/33652893 http://dx.doi.org/10.3390/jcm10050918 |
_version_ | 1783664497805754368 |
---|---|
author | Solanich, Xavier Fernández-Huerta, Miguel Basaez, Celeste Antolí, Arnau Rocamora-Blanch, Gemma Corbella, Xavier Santin, Miguel Alcaide, Fernando |
author_facet | Solanich, Xavier Fernández-Huerta, Miguel Basaez, Celeste Antolí, Arnau Rocamora-Blanch, Gemma Corbella, Xavier Santin, Miguel Alcaide, Fernando |
author_sort | Solanich, Xavier |
collection | PubMed |
description | Performance of the QuantiFERON-TB Gold Plus (QFT-Plus) assay could be affected by conditions of immune dysregulation. Little is known about the reliability of QTF-Plus in COVID-19 patients. Our aim was to determine the prevalence and the factors related to an indeterminate QFT-Plus test in COVID-19 hospitalized patients, and to analyze its relationship with in-hospital mortality. A retrospective analysis of all hospitalized COVID-19 patients on whom a QTF-Plus assay was performed in a tertiary care public hospital during the first epidemic wave in Spain (March–April 2020). Out of a total of 96 patients included, 34 (35.4%) had an indeterminate result, in all cases due to a lack of response in the mitogen control. Factors related to COVID-19 severity, such as higher lactate dehydrogenase (LDH) (odds ratio [OR] 1.005 [95% confidence interval [CI] 1.002–1.008]) and previous administration of corticosteroids (OR 4.477 [95% CI 1.397–14.345]), were independent predictors for indeterminate QFT-Plus assay. Furthermore, indeterminate results were more frequent among COVID-19 patients who died during hospitalization (29.1% vs. 64.7%; p = 0.005). We conclude that QFT-Plus assay yielded an unexpected, high prevalence of indeterminate results in severe COVID-19 patients. Factors related to worse COVID-19 outcome, such as LDH, as well as corticosteroid use before the QFT-Plus assay, seem to be predictors for an indeterminate result. The role of an indeterminate QFT-Plus result in predicting COVID-19 severity and mortality should be evaluated. |
format | Online Article Text |
id | pubmed-7956705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79567052021-03-16 Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome Solanich, Xavier Fernández-Huerta, Miguel Basaez, Celeste Antolí, Arnau Rocamora-Blanch, Gemma Corbella, Xavier Santin, Miguel Alcaide, Fernando J Clin Med Article Performance of the QuantiFERON-TB Gold Plus (QFT-Plus) assay could be affected by conditions of immune dysregulation. Little is known about the reliability of QTF-Plus in COVID-19 patients. Our aim was to determine the prevalence and the factors related to an indeterminate QFT-Plus test in COVID-19 hospitalized patients, and to analyze its relationship with in-hospital mortality. A retrospective analysis of all hospitalized COVID-19 patients on whom a QTF-Plus assay was performed in a tertiary care public hospital during the first epidemic wave in Spain (March–April 2020). Out of a total of 96 patients included, 34 (35.4%) had an indeterminate result, in all cases due to a lack of response in the mitogen control. Factors related to COVID-19 severity, such as higher lactate dehydrogenase (LDH) (odds ratio [OR] 1.005 [95% confidence interval [CI] 1.002–1.008]) and previous administration of corticosteroids (OR 4.477 [95% CI 1.397–14.345]), were independent predictors for indeterminate QFT-Plus assay. Furthermore, indeterminate results were more frequent among COVID-19 patients who died during hospitalization (29.1% vs. 64.7%; p = 0.005). We conclude that QFT-Plus assay yielded an unexpected, high prevalence of indeterminate results in severe COVID-19 patients. Factors related to worse COVID-19 outcome, such as LDH, as well as corticosteroid use before the QFT-Plus assay, seem to be predictors for an indeterminate result. The role of an indeterminate QFT-Plus result in predicting COVID-19 severity and mortality should be evaluated. MDPI 2021-02-26 /pmc/articles/PMC7956705/ /pubmed/33652893 http://dx.doi.org/10.3390/jcm10050918 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Solanich, Xavier Fernández-Huerta, Miguel Basaez, Celeste Antolí, Arnau Rocamora-Blanch, Gemma Corbella, Xavier Santin, Miguel Alcaide, Fernando Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome |
title | Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome |
title_full | Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome |
title_fullStr | Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome |
title_full_unstemmed | Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome |
title_short | Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome |
title_sort | clinical significance of indeterminate quantiferon-tb gold plus assay results in hospitalized covid-19 patients with severe hyperinflammatory syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956705/ https://www.ncbi.nlm.nih.gov/pubmed/33652893 http://dx.doi.org/10.3390/jcm10050918 |
work_keys_str_mv | AT solanichxavier clinicalsignificanceofindeterminatequantiferontbgoldplusassayresultsinhospitalizedcovid19patientswithseverehyperinflammatorysyndrome AT fernandezhuertamiguel clinicalsignificanceofindeterminatequantiferontbgoldplusassayresultsinhospitalizedcovid19patientswithseverehyperinflammatorysyndrome AT basaezceleste clinicalsignificanceofindeterminatequantiferontbgoldplusassayresultsinhospitalizedcovid19patientswithseverehyperinflammatorysyndrome AT antoliarnau clinicalsignificanceofindeterminatequantiferontbgoldplusassayresultsinhospitalizedcovid19patientswithseverehyperinflammatorysyndrome AT rocamorablanchgemma clinicalsignificanceofindeterminatequantiferontbgoldplusassayresultsinhospitalizedcovid19patientswithseverehyperinflammatorysyndrome AT corbellaxavier clinicalsignificanceofindeterminatequantiferontbgoldplusassayresultsinhospitalizedcovid19patientswithseverehyperinflammatorysyndrome AT santinmiguel clinicalsignificanceofindeterminatequantiferontbgoldplusassayresultsinhospitalizedcovid19patientswithseverehyperinflammatorysyndrome AT alcaidefernando clinicalsignificanceofindeterminatequantiferontbgoldplusassayresultsinhospitalizedcovid19patientswithseverehyperinflammatorysyndrome |